Anticipation mounts as Insmed's bronchiectasis therapy nears phase 3 completion from BioPharma-Reporter.com
The therapy has sparked significant anticipation within the medical community ahead of its phase 3 outcomes. A positive outcome from this study could lay the groundwork for regulatory approval, potentially reshaping the treatment landscape for …